SISRAM MED(01696.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of USD 1.16 million, turned into a loss from a profit YoY
NewTimeSpace News: August 19, 2026, SISRAM MED(01696.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 171.42 million, increased by 3.59% YoY; Net Profit stood at USD 1.05 million, YoY decrease of 88.28%; Profit Attributable to Shareholders stood at loss of USD 1.16 million, turned into a loss from a profit YoY; Basic Earnings Per Share (EPS) stood at loss of US cents 0.25.
In terms of profitability, SISRAM MED Gross Profit changed from USD 99.35 million in the same period last year to USD 97.22 million in the current period, decreased by USD 2.13 million; gross profit margin changed from 60.04% in the same period last year to 56.71% in the current period, decreased by 3.32 percentage points; net profit changed from USD 8.99 million in the same period last year to USD 1.05 million in the current period, decreased by USD 7.93 million; net profit margin changed from 5.43% in the same period last year to 0.61% in the current period, decreased by 4.82 percentage points.
In terms of earnings quality, SISRAM MED Operating Profit changed from USD 13.34 million in the same period last year to USD 4.34 million in the current period, decreased by USD 9 million; Operating Profit Margin changed from 8.06% in the same period last year to 2.53% in the current period, decreased by 5.53 percentage points.
In terms of financial soundness, SISRAM MED Debt-to-Asset Ratio changed from 22.99% in the same period last year to 25.86% in the current period, increased by 2.87 percentage points; Total Equity changed from USD 487.696 million in the same period last year to USD 501.225 million in the current period, increased by USD 13.53 million; Current Liabilities changed from USD 96.86 million in the same period last year to USD 126.2 million in the current period, increased by USD 29.34 million; Quick Ratio changed from 1.73 in the same period last year to 1.6 in the current period, decreased by 0.13 percentage points.
In terms of R&D investment focus, SISRAM MED R&D Expenses changed from USD 8.06 million in the same period last year to USD 6.69 million in the current period, decreased by USD 1.37 million; R&D to Total Revenue Ratio changed from 4.87% in the same period last year to 3.9% in the current period, decreased by 0.97 percentage points.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
